BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 34383278)

  • 1. Effects of Repeated Oral Administration of Esaxerenone on the Pharmacokinetics of Midazolam in Healthy Japanese Males.
    Toyama K; Furuie H; Kuroda K; Ishizuka T; Okuda Y; Shimizu T; Kato M; Igawa Y; Nishikawa Y; Ishizuka H
    Eur J Drug Metab Pharmacokinet; 2021 Sep; 46(5):685-694. PubMed ID: 34383278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of itraconazole and rifampicin on the single-dose pharmacokinetics of the nonsteroidal mineralocorticoid receptor blocker esaxerenone in healthy Japanese subjects.
    Kirigaya Y; Shiramoto M; Ishizuka T; Uchimaru H; Irie S; Kato M; Shimizu T; Nakatsu T; Nishikawa Y; Ishizuka H
    Br J Clin Pharmacol; 2020 Oct; 86(10):2070-2079. PubMed ID: 32250463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe.
    Schmitt C; Hofmann C; Riek M; Patel A; Zwanziger E
    Pharmacotherapy; 2009 Oct; 29(10):1175-81. PubMed ID: 19792991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-Drug Interaction Risk Assessment of Esaxerenone as a Perpetrator by In Vitro Studies and Static and Physiologically Based Pharmacokinetic Models.
    Yamada M; Ishizuka T; Inoue SI; Rozehnal V; Fischer T; Sugiyama D
    Drug Metab Dispos; 2020 Sep; 48(9):769-777. PubMed ID: 32616542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents : a randomized, open-label, crossover, single-centre study in healthy volunteers.
    Padhi D; Salfi M; Emery M
    Drugs R D; 2008; 9(5):335-43. PubMed ID: 18721002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single- and multiple-dose escalation study to assess pharmacokinetics, pharmacodynamics and safety of oral esaxerenone in healthy Japanese subjects.
    Kato M; Furuie H; Shimizu T; Miyazaki A; Kobayashi F; Ishizuka H
    Br J Clin Pharmacol; 2018 Aug; 84(8):1821-1829. PubMed ID: 29688582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absolute Bioavailability of Esaxerenone and Food Effects on its Pharmacokinetics After a Single Oral Dose in Healthy Japanese Subjects: An Open-Label Crossover Study.
    Kurata A; Furuie H; Ishizuka T; Nakatsu T; Shimizu T; Kato M; Nishikawa Y; Ishizuka H
    Adv Ther; 2019 Jul; 36(7):1618-1627. PubMed ID: 31119692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment.
    Kurata A; Yoshida T; Inoue M; Ishizuka T; Nakatsu T; Shimizu T; Kato M; Nishikawa Y; Ishizuka H
    Adv Ther; 2020 Jan; 37(1):253-264. PubMed ID: 31705436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic interactions of esaxerenone with amlodipine and digoxin in healthy Japanese subjects.
    Kirigaya Y; Shiramoto M; Ishizuka T; Uchimaru H; Irie S; Kato M; Shimizu T; Nakatsu T; Nishikawa Y; Ishizuka H
    BMC Pharmacol Toxicol; 2020 Jul; 21(1):55. PubMed ID: 32727577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of the Selective Orexin-1 Receptor Antagonist ACT-539313 on the Pharmacokinetics of the CYP3A Probe Drug Midazolam in Healthy Male Subjects.
    Berger B; Kaufmann P; Koch A; Dingemanse J
    J Clin Pharmacol; 2020 Jul; 60(7):931-941. PubMed ID: 32035014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers.
    Pentikis HS; Connolly M; Trapnell CB; Forbes WP; Bettenhausen DK
    Pharmacotherapy; 2007 Oct; 27(10):1361-9. PubMed ID: 17896891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin.
    Backman JT; Kivistö KT; Olkkola KT; Neuvonen PJ
    Eur J Clin Pharmacol; 1998 Mar; 54(1):53-8. PubMed ID: 9591931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjects.
    Hoch M; Hoever P; Alessi F; Theodor R; Dingemanse J
    Eur J Clin Pharmacol; 2013 Mar; 69(3):523-32. PubMed ID: 22990330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Pharmacokinetics of the CYP3A Substrate Midazolam After Steady-state Dosing of Delafloxacin.
    Paulson SK; Wood-Horrall RN; Hoover R; Quintas M; Lawrence LE; Cammarata SK
    Clin Ther; 2017 Jun; 39(6):1182-1190. PubMed ID: 28495029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data.
    Gupta P; Alvey C; Wang R; Dowty ME; Fahmi OA; Walsky RL; Riese RJ; Krishnaswami S
    Br J Clin Pharmacol; 2012 Jul; 74(1):109-15. PubMed ID: 22233204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microdosed midazolam for the determination of cytochrome P450 3A activity: Development and clinical evaluation of a buccal film.
    Kiene K; Hayasi N; Burhenne J; Uchitomi R; Sünderhauf C; Schmid Y; Haschke M; Haefeli WE; Krähenbühl S; Mikus G; Inada H; Huwyler J
    Eur J Pharm Sci; 2019 Jul; 135():77-82. PubMed ID: 31102650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the Drug-Drug Interaction Potential of Ensitrelvir Fumaric Acid with Cytochrome P450 3A Substrates in Healthy Japanese Adults.
    Shimizu R; Sonoyama T; Fukuhara T; Kuwata A; Matsuzaki T; Matsuo Y; Kubota R
    Clin Drug Investig; 2023 May; 43(5):335-346. PubMed ID: 37171749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects.
    Darwish M; Kirby M; Robertson P; Hellriegel ET
    Clin Pharmacokinet; 2008; 47(1):61-74. PubMed ID: 18076219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping.
    Link B; Haschke M; Grignaschi N; Bodmer M; Aschmann YZ; Wenk M; Krähenbühl S
    Br J Clin Pharmacol; 2008 Oct; 66(4):473-84. PubMed ID: 18537963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Effect of GS-548351 on the Pharmacokinetics of Midazolam Following Multiple Doses of ANS-6637 in Healthy Adults.
    Bunn HT; Rosenthal E; Mathur P; McLaughlin M; Proschan M; Vijan A; Aepfelbacher J; Kottilil S; Masur H; Kattakuzhy S; George JM
    J Clin Pharmacol; 2020 Dec; 60(12):1598-1605. PubMed ID: 32578227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.